Get the Stockscreener App
5.9852
3.00%
-0.1848
Y Mabs Therapeutics Inc stock is traded at $5.9852, with a volume of 269.40K.
It is down -3.00% in the last 24 hours and down -21.76% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$6.17
Open:
$6.16
24h Volume:
269.40K
Relative Volume:
0.74
Market Cap:
$276.35M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-12.21
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
+0.25%
1M Performance:
-21.76%
6M Performance:
-45.59%
1Y Performance:
-54.14%
1-Day Range:
$5.93
$6.22
1-Week Range:
$5.7098
$6.33
52-Week Range:
$5.7098
$20.90
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
212-847-9841
Address
230 PARK AVENUE, NEW YORK, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
5.99 | 276.35M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.48 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.98 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.61 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times
Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex
A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times
Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World
Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St
Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn
Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times
Y-mAbs Strengthens DANYELZA Team with Industry Veteran Doug Gentilcore as Business Unit Head - StockTitan
Y-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89 - MarketBeat
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA - Yahoo Finance
When (YMAB) Moves Investors should Listen - Stock Traders Daily
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp - Defense World
State Street Corp Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at J.P. Morgan Healthcare Conference 2025: Cancer Treatment Innovation Spotlight - StockTitan
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 13 '24 |
Sale |
13.47 |
65,000 |
875,550 |
97,681 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Sep 16 '24 |
Sale |
12.97 |
30,000 |
389,100 |
67,681 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):